Browsing Tag
Multiple myeloma
50 posts
Adaptive Biotechnologies sees stock surge after clonoSEQ EU certification
In a major development for the biotechnology sector, Adaptive Biotechnologies Corporation witnessed a remarkable 29% surge in its…
Johnson & Johnson’s CARVYKTI achieves significant milestone in multiple myeloma treatment
Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase…
GSK’s Blenrep shows significant efficacy in DREAMM-7 trial in multiple myeloma
GSK plc has unveiled promising results from the DREAMM-7 phase III trial, which highlights a notable advancement in…
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that…
GSK’s DREAMM-7 trial shows promising results for Blenrep in multiple myeloma
GSK plc has unveiled positive outcomes from the DREAMM-7 head-to-head phase III trial, evaluating Blenrep (belantamab mafodotin) as…
FDA greenlights Pfizer’s ELREXFIO for advanced multiple myeloma treatment
Pfizer Inc. has earned accelerated approval from the U.S. Food and Drug Administration (FDA) for its innovative drug,…
Aurobindo Pharma subsidiary receives FDA approval for Plerixafor Injection
Eugia Pharma Specialities Limited, a fully-owned subsidiary of India-based Aurobindo Pharma Limited, has received final approval from the…
Legend Biotech announces submission of CARVYKTI application to EMA for multiple myeloma
Legend Biotech has announced the submission of a Type II variation application to the European Medicines Agency (EMA)…
LaNova Medicines, AstraZeneca sign $600m worth licensing deal for LM-305
LaNova Medicines has signed an exclusive license deal worth over $600 million for its pre-clinical stage antibody drug…
Natco Pharma completes full US generic Revlimid lineup with new lenalidomide strengths
Natco Pharma and Teva Pharmaceuticals launch 2.5 mg and 20 mg generic lenalidomide in US, completing their Revlimid portfolio for multiple myeloma treatment.